Vaxcyte Inc. (PCVX) Performance and Fundamentals Dashboard tells a completely different story

Vaxcyte Inc. (NASDAQ: PCVX) stock jumped 2.06% on Tuesday to $50.50 against a previous-day closing price of $49.48. With 1.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $50.98 whereas the lowest price it dropped to was $49.08. The 52-week range on PCVX shows that it touched its highest point at $54.84 and its lowest point at $17.44 during that stretch. It currently has a 1-year price target of $66.29.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PCVX was up-trending over the past week, with a rise of 4.66%, but this was up by 16.41% over a month. Three-month performance surged to 17.44% while six-month performance rose 14.67%. The stock gained 92.60% in the past year, while it has gained 5.32% so far this year. A look at the trailing 12-month EPS for PCVX yields -3.42 with Next year EPS estimates of -3.35. For the next quarter, that number is -0.74. This implies an EPS growth rate of -78.70% for this year and -9.80% for next year. EPS is expected to grow by 1.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -57.40%.

Float and Shares Shorts:

At present, 86.21 million PCVX shares are outstanding with a float of 72.19 million shares on hand for trading. On Apr 27, 2023, short shares totaled 6.55 million, which was 7.04% higher than short shares on Mar 30, 2023. In addition to Mr. Grant E. Pickering M.B.A. as the firm’s Co-Founder, CEO & Director, Mr. Andrew L. Guggenhime M.B.A. serves as its Pres & CFO.

Institutional Ownership:

Through their ownership of 90.54% of PCVX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 45.04% of PCVX, in contrast to 37.43% held by mutual funds. Shares owned by individuals account for 3.44%. As the largest shareholder in PCVX with 12.15% of the stake, Fidelity Management & Research Co holds 11,019,483 shares worth 11,019,483. A second-largest stockholder of PCVX, The Vanguard Group, Inc., holds 6,446,042 shares, controlling over 7.11% of the firm’s shares. Janus Henderson Investors US LLC is the third largest shareholder in PCVX, holding 5,964,829 shares or 6.58% stake. With a 2.84% stake in PCVX, the American Funds Small Cap World Fu is the largest stakeholder. A total of 2,578,047 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.33% of PCVX stock, is the second-largest Mutual Fund holder. It holds 2,110,490 shares valued at 90.39 million. Vanguard Small Cap Index Fund holds 1.94% of the stake in PCVX, owning 1,756,888 shares worth 75.25 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, PCVX reported revenue of $0.00 and operating income of -$47.20M. The EBITDA in the recently reported quarter was -$44.62M and diluted EPS was -$0.80.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PCVX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PCVX analysts setting a high price target of $72.00 and a low target of $58.00, the average target price over the next 12 months is $66.29. Based on these targets, PCVX could surge 42.57% to reach the target high and rise by 14.85% to reach the target low. Reaching the average price target will result in a growth of 31.27% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded PCVX stock several times over the past three months with 5 Buys and 3 Sells. In these transactions, 119,875 shares were bought while 6,015 shares were sold. The number of buy transactions has increased to 33 while that of sell transactions has risen to 62 over the past year. The total number of shares bought during that period was 369,060 while 224,233 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *